3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
53
Lymphoma, Mantle-Cell
34
Lymphoma, Large B-Cell, Diffuse
18
Lymphoma, Follicular
18
Lymphoma
15
Lymphoma, Non-Hodgkin
13
Waldenstrom Macroglobulinemia
12
Lymphoma, B-Cell
12
Recurrence
9
Lymphoma, B-Cell, Marginal Zone
9
Leukemia
6
Bronchiolitis Obliterans Syndrome
6
Multiple Myeloma
5
Leukemia, Lymphoid
5
Leukemia, B-Cell
5
Hodgkin Disease
5
Hematologic Neoplasms
4
Burkitt Lymphoma
4
Neoplasms
3
Graft vs Host Disease
3
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Chromosome 17 deletion
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Interventions
Cyclophosphamide
7
blinatumomab
6
Cytarabine
6
fludarabine
5
Mercaptopurine
5
Methotrexate
4
fludarabine phosphate
3
Vincristine
3
Rituximab
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Drug Therapy
3
Dexamethasone
3
Daunorubicin
3
Asparaginase
3
Whole-Body Irradiation
2
Vindesine
2
Thioguanine
2
Teniposide
2
Stem Cell Transplantation
2
Prednisolone
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Interleukin-2
2
Doxorubicin
2
Cladribine
2
Blood Specimen Collection
2
Azacitidine
2
tisagenlecleucel
1
thymoglobulin
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasm, Residual
×
ibrutinib
×
Clear all
NCT02666898
2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2
Completed
135 enrolled